Gentris’ senior management team is comprised of highly qualified professionals with established and diverse experience in the fields of pharmacogenomics, pharmacology, clinical drug development, laboratory operations, and molecular biology.
Amelia Wall Warner, PharmD, President and CEO
Amelia Wall Warner, PharmD joined Gentris in 2013 as President. Dr. Warner oversees the U.S. operations, leads the development of new service offerings, and develops scientific education and training programs for biobanking and pharmacogenomics. As a key member of the management team, she works with Gentris leaders to set the strategic vision for the company and to ensure it continues to be on the cutting-edge of genomic medicine. Dr. Warner was most recently the Head of Clinical Pharmacogenomics and Clinical Specimen Management for Merck Research Laboratories (MRL). In her position, she oversaw all clinical pharmacogenomics projects, oversaw policies and procedures for biosample collection and storage for clinical trial samples, and was the MRL Pharmacogenomics Expert for the Translational Science Research Network. Amelia was the MRL key expert for global regulation for genetic research and human specimen usage regulation/law. Amelia is the CEO and Founder of Global Specimen Solutions, Inc., a past chair of the Industry Pharmacogenomics Working Group (I-PWG), and a PhRMA representative to ICH E16- Genomic Biomarkers Related to Drug Response. As an industry expert, she has participated in numerous meetings and conferences as a key opinion leader on applying pharmacogenomics in drug development, best practices for collecting, maintaining, and maximizing return-on-investment for clinical sample biobanks in all phases of clinical trials, and appropriate informed consent to enable future use and testing. Dr. Warner completed a residency in Pediatric Pharmacotherapy at St. Jude Children’s Research Hospital with John Rodman, PharmD and a fellowship in Clinical Pharmacology/ Pharmacogenomics at St. Jude Children’s Research Hospital with William Evans, PharmD. Amelia holds a PharmD from the University of North Carolina at Chapel Hill and a Bachelor of Science in Biology from Wake Forest University.
L. Scott Clark, Ph.D., Vice President, Global Scientific Operations
Dr. Clark is a pioneer and industry leader in the application of pharmacogenomics to drug development. He has more than 16 years of experience at pharmaceutical and clinical research companies in technology assessment and applications, assay development, laboratory management, and project management. Dr. Clark joined Gentris Corporation from DNA Sciences in September 2001 as laboratory director and was promoted to Chief Scientific Officer in July 2008. He worked at Intek Labs as Clinical Study Director and was instrumental in the success of PPGx, a joint venture between Intek-PPD and Axys Pharmaceuticals.
Dr. Clark earned his Bachelor’s degree in Biology at Hobart College and earned his Ph.D. degree in Cell and Molecular Biology from the University of Vermont where his thesis work focused on human mutation. He completed his post-doctoral training in genetic toxicology at the University of North Carolina and the US EPA.
Reporting to the CEO, Dr. Clark is responsible for the scientific and technological developments and emerging issues germane to the strategy and success of the Company.
John Doyle, Vice President, Information Technology
John Doyle was hired as Vice President of Information Technology to drive the evolution of Gentris’ IT infrastructure and lead the implementation of the LabmatrixTM and Qiagram™ software. John brings with him over 25 years of experience at IBM, which he will leverage as he continues to grow and enhance Gentris’ IT infrastructure. John served as a programmer at IBM for 14 years assuming increasing responsibilities before transitioning into a software engineer role in 2001. He has extensive experience in all phases of the software development lifecycle including the design, configuration, deployment, and implementation of Java Enterprise systems. Under John’s leadership, Gentris will continue to improve its IT systems and infrastructure in order to meet client demands and expand the company’s informatics and bioinformatics capabilities. John received his Bachelor’s of Science degree in Computer and Information Science from Bloomsburg University of Pennsylvania. He received his Master’s of Science degree in Computer and Information Science from Villanova University.
Pamela S. Prior, MBA, CPA, CFO
An accomplished financial leader with over 20 years of experience in both Fortune 50 (Life Sciences) and middle market publicly-traded and Private-Equity held companies, Pam Prior joined Gentris in 2013 as its Chief Financial Officer. Pam is focused on defining and maintaining the financial infrastructure to support the Gentris vision for continued growth and transformation. Over 17 years, Pam held a number of progressively responsible positions at DuPont, DuPont-Merck and DuPont Pharmaceuticals, and with the packaging subsidiary of Cardinal Health as their Corporate Controller. She was subsequently recruited to join the $250 million Tasty Baking Company in Philadelphia as their Director of Internal Control and Corporate Controller. Most recently, from 2006 – 2013, she was Chief Financial Officer for Greatwide Truckload Management, a $250 million subsidiary of a $1.2 billion privately held transportation logistics company. Pam has extensive experience working internationally; and a robust knowledge of Sarbanes Oxley (SOX) compliance. She has been sought after as a government agency (PCAOB) advisor and public speaker, particularly related to internal control issues for small and mid-market companies. She was also a member of the task force that drafted and finalized the 2006 COSO publication “Internal Control over Financial Reporting – Guidance for Smaller Public Companies”. Pam earned her MBA and her BS Degree in Accounting from The University of Delaware; and she maintains an active CPA with the Commonwealth of Pennsylvania.
Heath Knight, Ph.D., Vice President, Corporate Development
Heath Knight, Ph.D., will lead business development, sales, and marketing. Her focus will be driving further expansion of the company’s genomic testing and biorepository services in domestic and international markets. A key focus will be in China where the company opened its first international facility in November, 2013. Dr. Knight was previously with Gentris as vice president of sales and marketing and left in 2008 to join Third Wave Technologies as executive director of genomic services and general manager of the newly formed pharmacogenomic Services business unit. She was recently strategic director of companion diagnostics for LabCorp’s Clinical Trials. Over the past 15 years, Dr. Knight has held senior management positions in business development and sales as well laboratory operations in leading specialty genomic testing providers. She earned a Ph.D. degree in Human Genetics from the Medical College of Virginia and completed postdoctoral training at Baylor College of Medicine and the Mayo Clinic.